Human Papillomavirus-Related Carcinoma Clinical Trial
Official title:
MeFirst: A Tailored Intervention to HPV Vaccine Decision Making
This study will test whether a tailored, online educational intervention increases HPV vaccine uptake and intent among female college students.
MeFirst is the first web-based, online, educational tool designed to promote Human Papillomavirus (HPV) vaccine awareness and understanding in an effort to improve HPV vaccine intent and uptake among female university students. HPV is the most common sexually transmitted infection and causes genital warts and cancer. The HPV vaccine has been recommended for girls ages 11-26 since 2006, yet vaccination rates remain low. Tailored online interventions may be more effective tools to promote behavior change among college students than traditional static interventions. The proposed study is a randomized controlled trial testing the efficacy of the MeFirst tool vs. standard static educational material on increasing HPV vaccination intent and uptake among female university students aged 18-26. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02379520 -
HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA
|
Phase 1 | |
Completed |
NCT02624349 -
Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients
|
Phase 4 | |
Recruiting |
NCT04474821 -
HPV Educational Intervention to Increase Acceptance and Completion of Free HPV Vaccination Among Underserved Adults
|
Phase 4 | |
Withdrawn |
NCT05472220 -
Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma
|
Phase 1 | |
Active, not recruiting |
NCT02568566 -
Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants
|
Phase 2 | |
Recruiting |
NCT05232851 -
A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05985681 -
Testing RG1-VLP Vaccine to Prevent HPV-related Cancers
|
Phase 1 | |
Completed |
NCT04189003 -
Molecular Signatures of HPV+ ORL Cancers (OROPAP)
|
||
Recruiting |
NCT04927650 -
Prevention and Early Detection of Cervical Cancer Through Self-Administered Screening
|
||
Recruiting |
NCT05831540 -
Clinical Decision Support Tools to Increase Human Papillomavirus (HPV) Vaccination in Adolescents in Pharmacies
|
N/A | |
Active, not recruiting |
NCT04580446 -
HYHOPE: De-intensified Hypofractionated Radiation Therapy for HPV-associated Oropharynx Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03634267 -
MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer
|
Phase 1 | |
Not yet recruiting |
NCT04142398 -
Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men
|
||
Completed |
NCT04880837 -
Human Papillomavirus Education Programs
|
N/A |